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The importance of antibiotic resistance and appropriate
initial therapy?
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Scott T. Micek, PharmDd, Marin H. Kollef, MDc,
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Abstract
Bacteremic pneumonia is usually associated with greater mortality. However, risk factors associated with hospital mortality in
bacteremic pneumonia are inadequately described.
The study was a retrospective cohort study, conducted in Barnes-Jewish Hospital (2008–2015). For purposes of this investigation,
antibiotic susceptibility was determined according to ceftriaxone susceptibility, as ceftriaxone represents the antimicrobial agent
most frequently recommended for hospitalized patients with community-acquired pneumonia as opposed to nosocomial
pneumonia. Two multivariable analyses were planned: the ﬁrst model included resistance to ceftriaxone as a variable, whereas the
second model included the various antibiotic-resistant species (methicillin-resistant Staphylococcus aureus, Pseudomonas
aeruginosa, and Enterobacteriaceae).
In all, 1031 consecutive patients with bacteremic pneumonia (mortality 37.1%) were included. The most common pathogens
associated with infection were S aureus (34.1%; methicillin resistance 54.0%), Enterobacteriaceae (28.0%), P aeruginosa (10.6%),
anaerobic bacteria (7.3%), and Streptococcus pneumoniae (5.6%). Compared with ceftriaxone-susceptible pathogens (46.8%),
ceftriaxone-resistant pathogens (53.2%) were signiﬁcantly more likely to receive inappropriate initial antibiotic treatment (IIAT) (27.9%
vs 7.1%; P<0.001) and to die during hospitalization (41.5% vs 32.0%; P=0.001). The ﬁrst logistic regression analysis identiﬁed IIAT
with the greatest odds ratio (OR) for mortality (OR 2.2, 95% conﬁdence interval [CI] 1.5–3.2, P<0.001). Other independent predictors
of mortality included age, mechanical ventilation, immune suppression, prior hospitalization, prior antibiotic administration, septic
shock, comorbid conditions, and severity of illness. In the second multivariable analysis that included the antibiotic-resistant species,
IIAT was still associated with excess mortality, and P aeruginosa infection was identiﬁed as an independent predictor of mortality (OR
1.6, 95% CI 1.1–2.2, P=0.047), whereas infection with ceftriaxone-resistant Enterobacteriaceae (OR 0.6, 95% CI 0.4–1.0, P=
0.050) was associated with lower mortality.
More than one-third of our patients hospitalized with bacteremic pneumonia died. IIAT was identiﬁed as the most important risk
factor for hospital mortality and the only risk factor amenable to potential intervention. Speciﬁc antibiotic-resistant pathogen species
were also associated with mortality.
Abbreviations: APACHE = Acute Physiology and Chronic Health Evaluation, CAP = community-acquired pneumonia, CfRE =
ceftriaxone-resistant Enterobacteriaceae, GNB = Gram-negative bacteria, HAP = hospital-acquired pneumonia, HCAP =
healthcare-associated pneumonia, IIAT= inappropriate initial antibiotic treatment, MDR=multidrug-resistant, MLR=multiple logistic
regression, OR = odds ratio, VAP = ventilator-associated pneumonia.
Keywords: antibiotics, outcomes resistance, pneumonia
1. Introduction
Pneumonia remains one of the most important infectious diseases
affecting US adults.[1] It is associated with signiﬁcant hospital
length of stay, cost, morbidity, and mortality that does not seem
to have improved over the past 2 decades despite important
medical advances.[2] Bacteremia complicating pneumonia
increases in prevalence among patients with greater severity of
disease, becoming most common among critically ill patients.[3–7]
Nosocomial bacteremic pneumonia seems to have the greatest
risk of mortality and excess length of stay, especially ventilator-
associated pneumonia (VAP) and healthcare-associated pneu-
monia (HCAP).[4,5,8–12] One important factor contributing to
high mortality is the antimicrobial resistance patterns exhibited
by the microbes responsible for pneumonia.[13] Increasing
antimicrobial resistance promotes greater administration of
inappropriate initial antibiotic treatment (IIAT) (i.e., an
antibiotic regimen without activity against the offending
pathogen as demonstrated by in vitro susceptibility testing).[14]
This has resulted in the increasing empiric use of broad-spectrum
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antimicrobial agents for the treatment of pneumonia to provide
more appropriate initial treatment.
Recent studies have attempted to better deﬁne the risk factors
for pneumonia attributed to antibiotic-resistant pathogens so
that broad-spectrum antimicrobial therapy can be more
accurately targeted.[15–20] Unfortunately, the identiﬁed risk
factors overlap for antibiotic-resistant Gram-positive pathogens
like methicillin-resistant Staphylococcus aureus (MRSA) and
antibiotic-resistant Gram-negative bacilli (GNB), including
Pseudomonas aeruginosa, Acinetobacter spp, and antibiotic-
resistant Enterobacteriaceae. To date, few studies have attempted
to establish speciﬁc risk factors or combinations of risk factors
that predict ceftriaxone resistance, the cornerstone of antimicro-
bial therapy for community-acquired pneumonia (CAP). Predict-
ing ceftriaxone resistance would implicitly modify empirical
therapy in patients with suspected pneumonia. Therefore, we
sought to identify risk factors for mortality in patients with
bacteremic pneumonia and risk factors for various ceftriaxone-
resistant microbes.
2. Methods
2.1. Study population and data Source
The study was conducted at Barnes-Jewish Hospital, an academic
referral center of 1250 beds. This investigation was approved by
the Washington University School of Medicine Human Studies
Committee and the University of New Mexico Human Research
Protections Ofﬁce, and the need for informed consent was
waived. All hospitalized patients between January 2008 and
April 2015 with pneumonia complicated by secondary bacter-
emia were eligible for inclusion. Data were collected from the
hospital’s electronic health record system provided by the Center
for Clinical Excellence, BJC Healthcare.
2.2. Study outcomes
The primary objective of this study was to determine whether
markers of antibiotic resistance (ceftriaxone resistance) and
speciﬁc antibiotic-resistant bacterial species (MRSA, P aerugi-
nosa, ceftriaxone-resistant Enterobacteriaceae [CfRE]) are risk
factors for mortality in patients with bacteremic pneumonia. The
secondary objective of this study was to identify variables
predicting bacteremic pneumonia due to speciﬁc antibiotic-
resistant bacteria (MRSA, P aeruginosa, CfRE).
2.3. Deﬁnitions and study design
Adult patients (age>18 years) were identiﬁed retrospectively with
bacteremic pneumonia in accordance with the American Thoracic
Society’s position statement on nosocomial pneumonia.[21] The
diagnosis included presence of a new or progressive radiographic
inﬁltrate and at least 2 of the following clinical features: fever
greater than 38°C, leukocytosis (>10109cells/L), leukopenia
(4109cells/L), or purulent secretions. The presence of a new or
progressive radiographic inﬁltrate was based on the interpretation
of the chest radiograph by board-certiﬁed radiologists blinded to
the study. All patient charts were reviewed by 1 of the investigators
to conﬁrm the radiographic ﬁndings (MHK) and to identify
patients meeting the case deﬁnition for pneumonia (CVG, STM).
Patients also had to have bacteremia deﬁned as presence of at least
1 positive blood culture for true pathogens. Septic shock was
deﬁned as the need for vasopressors (norepinephrine, dopamine,
vasopressin, epinephrine, phenylephrine). Only the ﬁrst episode of
bacteremicpneumoniawas recorded.Antimicrobial treatmentwas
classiﬁed as appropriate if the regimen had in vitro activity
demonstrated against the isolated pathogens and as IIAT if the
regimendidnot demonstrate invitro activity. Invitro antimicrobial
susceptibility reliedonstandardpublishedbreakpoints.[22] Patients
with pneumonia and bacteremia due to a nonpneumonic source
(e.g., patient with P aeruginosa pneumonia and MRSA catheter-
associated blood stream infection) were excluded from the study
cohort.
Immunosuppression was deﬁned as the acquired immune
deﬁciency syndrome, solid organ or bone marrow transplant,
hematologic malignancies, solid cell cancers treated with
chemotherapy or radiation, long-term corticosteroids (>10mg/
d), and other immunosuppressive drugs (e.g., biologics for
rheumatologic disorders). For purposes of this investigation,
antibiotic susceptibility was determined according to ceftriaxone
susceptibility, as ceftriaxone represents the antimicrobial agent
most frequently recommended for hospitalized patients with CAP
as opposed to nosocomial pneumonia.[2,21] Multidrug-resistant
(MDR) pathogens had to demonstrate in vitro resistance to at
least 1 agent from 3 distinct classes of antimicrobials that would
normally have activity against that bacterium.[23]
2.4. Antimicrobial monitoring
From January 2002 through the present, Barnes-Jewish Hospital
utilized an antibiotic control program to help guide antimicrobial
therapy for bacterial infections. During this time, the use of
cefepime, gentamicin, or vancomycin was unrestricted. However,
initiation of intravenous ciproﬂoxacin, imipenem, meropenem,
piperacillin/tazobactam, linezolid, or daptomycin was restricted
and required preauthorization from either a clinical pharmacist
or infectious diseases physician. Each intensive care unit (ICU)
had a clinical pharmacist who reviewed all antibiotic orders to
insure that dosing and interval of antibiotic administration was
adequate for individual patients based on body size, renal
function, and the resuscitation status of the patient. After daytime
hours, the on-call infectious diseases physician reviewed and
approved the antibiotic orders.
The initial antibiotic dosages employed for the treatment of
bacterial infections at the Barnes-Jewish Hospital were as follows:
cefepime, 1 to 2g every 8hours; piperacillin–tazobactam, 4.5g
every 6hours; imipenem, 0.5g every 6hours; meropenem, 1 to 2g
every 8hours; ciproﬂoxacin, 400mg every 8hours; gentamicin, 5
mg/kg once daily; vancomycin, 15mg/kg every 12hours; linezolid,
600mg every 12hours; and daptomycin, 6mg/kg every 24hours
(daptomycin was not prescribed for pneumonia).
2.5. Antimicrobial susceptibility testing
The microbiology laboratory performed antimicrobial suscepti-
bility of the bacterial isolates using the disk diffusion method
according to guidelines and breakpoints established by the
Clinical Laboratory and Standards Institute and published during
the inclusive years of the study.[22] All classiﬁcations of antibiotic
resistance were based on in vitro susceptibility testing using these
established breakpoints.
2.6. Data collection and statistical analyses
We collected demographic characteristics (age, race, sex, nursing
home residence), comorbidities of interest (hemodialysis, immu-
nosuppression, Charlson score, previous hospitalizations within
90 days, previous bacteremia within 90 days, and prior
Guillamet et al. Medicine (2016) 95:35 Medicine
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antibiotics within 30 days), clinical features (Acute Physiology
and Chronic Health Evaluation [APACHE] II, need for vaso-
pressors or mechanical ventilation, central vein catheter,
duration of hospitalization before bacteremia), microbiology
data (culture results and antibiotic susceptibility), treatment
variables, and outcome data (hospital mortality and discharge
location).
The sample size was determined by a convenience sample of all
the patients with bacteremic pneumonia identiﬁed at our
institution during the study period. Continuous variables were
expressed as means and standard deviations (SDs), or medians
and interquartile range (IQR), when appropriate. The t test and
1-way analysis of variance (ANOVA) tests were used to
analyze normally distributed continuous variables, whereas the
Mann–WhitneyU and Kruskal–Wallis tests were used to analyze
non-normally distributed continuous variables. Categorical data
were reported as frequency distributions, and analyzed using the
chi-square test or McNemar test. We performed univariable and
stepwise backward automatic elimination multivariable logistic
regression (MLR) analyses to determine variables associated with
mortality and variables that contributed to infections caused by
MRSA, P aeruginosa, and CfRE.We analyzed 2MLRmodels for
mortality. The ﬁrst model included resistance to ceftriaxone as a
variable, whereas the second model included the various
antibiotic-resistant species (MRSA, P aeruginosa, and Enter-
obacteriaceae). All variables that reached a signiﬁcance threshold
of 0.2 in univariable analyses were entered in the multivariable
models. We performed diagnostics for colinearity and tested for
interactions. Missing values were 7.7% and were handled by
multiple imputations. Goodness of ﬁt was estimated using the
Hosmer–Lemeshow c-statistic. P values less than 0.05 were
considered statistically signiﬁcant, and all tests were 2-tailed. All
analyses were done using STATA/SE 13.1 (STATA Corp LP,
College Station, TX).
3. Results
One thousand thirty-one consecutive patients with bacteremic
pneumonia were identiﬁed (Fig. 1). The majority were white
males admitted from home, with 10% of the patients residing in a
nursing home before admission (Table 1). There were 159
(15.4%) patients with CAP (mortality 27.0%) and 429 (41.6%)
patients with HAP (mortality 41.5%). Risk factors for potential
infection with antibiotic-resistant pathogens included hemodial-
ysis (9.8%), immunosuppression (34.1%), prior hospitalization
(44.7%), and prior antibiotic use (53.1%). The median duration
of hospitalization at which the diagnosis of bacteremic pneumo-
nia occurred was hospital day 1 (IQR 0–9 days). The most
common pathogens were S aureus (34.1%; methicillin resistance
54.0%), Enterobacteriaceae (28.0%), P aeruginosa (10.6%),
anaerobic bacteria (7.3%), and Streptococcus pneumoniae
(5.6%). Extended-spectrum b-lactamase (ESBL)-producing bac-
teria and carbapenemase-producing bacteria were uncommon.
However, ceftriaxone-resistant bacteria accounted for 53.2%.
Bacteremic pneumonia was associated with MRSA in 190
(18.4%) patients, P aeruginosa in 109 (10.6%) patients, and
CfRE in 110 (10.7%) patients, with these 3 pathogens accounting
for 74.5% of the ceftriaxone-resistant group. Patients infected
with ceftriaxone-resistant pathogens were signiﬁcantly more
likely to be immunosuppressed, previously hospitalized or treated
with antibiotics, admitted from a nursing home, have longer
hospital stays before the onset of infection, require hemodialysis,
Figure 1. Analysis plan. CfRE=ceftriaxone-resistant Enterobacteriaceae, MRSA=methicillin-resistant Staphylococcus aureus.
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central vein catheters, and mechanical ventilation (Table 2).
Patients infected with ceftriaxone-resistant pathogens were also
more likely to receive IIAT (27.9% vs 7.1%; P<0.001) and to
have greater hospital mortality (41.5% vs 32.0%; P=0.001).
Among the patients infected with ceftriaxone-resistant patho-
gens, P aeruginosa was associated with the highest rates of
immunosuppression and prior hospitalization, whereas infection
with CfRE was associated with the highest rates of prior
antibiotic exposure, duration of hospitalization before infection,
and presence of a central vein catheter (Table 3). Bacteremic
pneumonia due to CfRE had the highest rate of IIAT, whereas P
aeruginosa was associated with the greatest risk of mortality.
Independent risk factors associated with MRSA, P aeruginosa,
and CfRE are shown in Table 4, conﬁrming the associations
observed in the univariable analyses for P aeruginosa and CfRE
(see Supplemental Tables 1 through 4 for the univariate analyses,
http://links.lww.com/MD/B237).
3.1. Logistic regression analysis for hospital mortality
The 2 MLR analyses performed to identify factors associated
with hospital mortality, along with the univariable analyses, are
shown in Table 5. The ﬁrst logistic regression analysis for hospital
mortality, which included resistance to ceftriaxone as an
independent variable, identiﬁed IIAT with the greatest odds
ratio (OR) for hospital mortality (OR 2.2, 95% conﬁdence
interval [CI] 1.5–3.2, P<0.001) (Table 5). Other independent
predictors of hospital mortality included age, mechanical
ventilation, immune suppression, prior hospitalization, prior
antibiotic administration, septic shock, comorbid conditions, and
severity of illness. Resistance to ceftriaxone was not indepen-
dently associated with mortality. The second MLR analysis,
which included speciﬁc pathogens (P aeruginosa, CfRE, MRSA)
as independent variables, also found IIAT to be associated with
the greatest OR for hospital mortality (OR 2.3, 95% CI 1.6–3.2,
P<0.001) and demonstrated that infection with P aeruginosa
was independently associated with greater mortality, whereas
CfRE infection was associated with a lower risk of mortality
(Table 5).
4. Discussion
In our study, we found that more than one-third of patients with
bacteremic pneumonia died during their hospitalization. IIAT
was identiﬁed as the most important risk factor for hospital
mortality and the only risk factor potentially amenable to
intervention. We also identiﬁed differences in risk factors for
infection with various ceftriaxone-resistant bacteria. However,
the risk factors were general markers of disease severity or tended
to overlap between pathogens as shown by prior hospitalization
being associated with P aeruginosa infection and prior antibiotic
use predicting infection with CfRE. These ﬁndings support the
clinical importance of timely appropriate antibiotic treatment to
optimize clinical outcomes regardless of the antibiotic-resistant
pathogen causing bacteremic pneumonia.
Several earlier studies have attempted to develop prediction
models for infection attributed to antibiotic-resistant bacteria in
patients with pneumonia. The deﬁnitions used for antibiotic-
resistant pathogens were either similar to ours centering on
resistance to drugs empirically used in the treatment of CAP,[17]
whereas others were more stringent including only MRSA, P
aeruginosa, and ESBL or carbapenemase-producing Enterobac-
teriaceae.[15,16,18,20] From a practical treatment perspective
determining which empiric antibiotic regimen to administer to
patients with pneumonia usually hinges on whether the clinician
considers the offending pathogens to be resistant to the typical
empiric regimen prescribed for CAP (ceftriaxone plus amacrolide
Table 1
Demographics, clinical characteristics, microbiology, and hospital
course among 1031 patients diagnosed with bacteremia second-
ary to pneumonia between 2008 and 2015.
Characteristic All patients (N=1031)
Age, y, mean±SD 58.7±16.1
Sex: male 600 (58.2%)
Race
∗
White 678 (65.8%)
African American 305 (29.6%)
Hispanic 1 (0.1%)
Admission source†
Admission from nursing home 103 (10.0%)
Admission from home 701 (68.0%)
Transferred from a different hospital 215 (20.9%)
Pneumonia type
CAP 159 (15.4%)
HAP 429 (41.6%)
Duration of hospitalization before infection, d, median (IQR) 1 (0–9)
Bacteria species
Staphylococcus aureus 352 (34.1%)
MRSA 190 (18.4%)
VISA 15 (1.5%)
Enterobacteriaceae‡ 289 (28.0%)
Anaerobesx 75 (7.3%)
Streptococcus pneumoniae 57 (5.6%)
Pseudomonas aeruginosa 109 (10.6%)
Acinetobacter spp 21 (2.0%)
Stenotrophomonas maltophilia 25 (2.4%)
Resistance to ceftriaxone 549 (53.2%)
ESBL producers 16 (1.6%)
Carbapenemase producers 3 (0.3%)
Comorbidities
Hemodialysis 101 (9.8%)
Immunosuppression 351 (34.0%)
Charlson score 5.5±3.4
Prior hospitalization 461 (44.7%)
Prior antibiotics 547 (53.1%)
Recent surgery
Abdominal surgery 86 (8.3%)
Nonabdominal surgery 160 (15.5%)
Central vein catheter 493 (47.8%)
Mechanical ventilation 452 (43.8%)
ICU 682 (66.2%)
Septic shock 561 (54.4%)
Peak WBC103, cells/mL, median (IQR) 17.4 (10.1–29.7)
APACHE II score, mean±SD 16±6.3
Inappropriate initial antibiotic treatment 187 (18.1%)
Disposition
Discharge to home 274 (26.6%)
Discharge to nursing home/ rehabilitation 343 (33.3%)
Mortality 382 (37.1%)
Community-acquired pneumonia: patients were admitted from home, no previous hospitalizations
within 90 days, no previous antibiotics, no chronic hemodialysis, duration of hospitalization before
bacteremic pneumonia of 2 days.
HAP deﬁnition: duration of hospitalization before bacteremic pneumonia >2 days.
APACHE=Acute Physiology and Chronic Health Evaluation, CAP= community-acquired pneumonia,
ESBL= extended spectrum beta-lactamase, HAP=hospital-acquired pneumonia, ICU= intensive care
unit, IQR= interquartile range, MRSA=methicillin resistant Staphylococcus aureus, SD= standard
deviation, VISA= vancomycin-intermediate Staphylococcus aureus, WBC=white blood cell count.
∗
Also Asian, native American, unknown.
† Also prison, unknown.
‡ Enterobacteriaceae: Serratia, Enterobacter, Citrobacter, Klebsiella, Escherichia coli, Proteus species.
x Anaerobes: Moraxella, Morganella, Prevotella, Fusobacterium, Bacteroides, Clostridium species.
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or a respiratory quinolone).[2] These earlier studies have
attempted to guide this decision-making process by identifying
risk factors for antibiotic resistance. However, they primarily
attempted to juxtapose CAP and HCAP among patients directly
admitted to the hospital with pneumonia, excluding cases of HAP
andVAP. Although themodels in these studies seemed to perform
well in the initial cohorts from which they were developed, their
predictive accuracy was less robust when applied to other cohorts
of pneumonia patients.[24,25]
The majority of risk factors previously identiﬁed for antibiotic
resistance in patients with pneumonia converge towards previous
antibiotic or hospital exposures, impaired functional status, and
the acuity of the clinical presentation. It is usually not 1 single risk
factor, with the possible exception of immunosuppression, but
the presence of 2 or more risk factors that increases the hazard for
drug-resistant pathogens.[15–18,20] Understanding that the same
risk factors might carry different weights and interact differently
in a prediction model, some studies have tried to examine the
predisposing conditions for bacterial species of interest, with
MRSA and P aeruginosa being commonly targeted.[18,26–29]
Unfortunately, none of these prediction scores have been
validated in prospective studies aimed at guiding the administra-
tion of empiric antibiotic treatment for suspected pneumonia.
Our study attempts to expand upon earlier studies by
identifying risk factors for bacteremic pneumonia attributed to
CfRE. The rate of previous antibiotic use was high across all
resistant pathogens in our study population, but was highest for
CfRE (74.5%). CfRE infections were also more likely to occur
later during the hospitalization. However, only prior antibiotic
exposure and presence of a central vein catheter were found to
independently predict the presence of CfRE infection. Antibiotic-
resistant Enterobacteriaceae (ESBL or carbapenemase-producing
strains) originating in the community setting have recently been
found to be an important etiology of inappropriately treated
infections, making clinical prediction of such pathogens
problematic.[30–32] Moreover, the presence of immunosuppres-
sion is associated with infection attributed to all resistant
pathogens including MRSA and Gram-negative bacilli (P
aeruginosa, Acinetobacter baumanii, Stenotrophomonas malto-
philia, Klebsiella spp, Serratia spp).[19] In our population,
immunosuppression characterized bacteremic pneumonia caused
by P aeruginosa, whereas earlier studies identiﬁed Pseudomonas
pneumonia to develop as a secondary infection after previous
hospitalization, in immunocompromised hosts with damaged
lungs, in previously colonized patients, and in those with
debilitating comorbidities like cerebrovascular disease.[33–39]
Table 2
Comparison between ceftriaxone-susceptible and ceftriaxone-resistant bacteria.
Characteristic Ceftriaxone-susceptible (n=482) Ceftriaxone-resistant (n=549) P
Age, y, mean±SD 58.9±16.4 58.4±15.8 0.636
Male sex 287 (59.5%) 313 (57.0%) 0.411
Race
∗
0.775
White 310 (64.3%) 368 (67.0%)
African American 150 (31.1%) 155 (28.2%)
Pneumonia type
CAP 107 (22.2%) 52 (9.5%) <0.001
HAP 163 (33.8%) 266 (48.5%) <0.001
Nursing home residence 37 (7.7%) 66 (12.0%) 0.020
Hemodialysis 36 (7.5%) 65 (11.8%) 0.018
Immunosuppression 147 (30.5%) 204 (37.2%) 0.026
Prior hospitalization 184 (38.2%) 277 (50.5%) <0.001
Prior antibiotics 209 (43.4%) 338 (61.6%) <0.001
Charlson score 5.5±3.5 5.5±3.4 0.872
Central vein catheter 187 (38.8%) 306 (55.7%) <0.001
Surgery 0.004
Abdominal 39 (8.1%) 47 (8.6%)
Nonabdominal 56 (11.7%) 104 (18.9%)
Duration of hospitalization before bacteremia, d, median (IQR) 0 (0–5) 2 (0–14) 0.001†
Mechanical ventilation 191 (39.6%) 261 (47.5%) 0.011
ICU 308 (63.9%) 374 (68.1%) 0.153
Septic shock 261 (54.1%) 300 (54.6%) 0.873
APACHE II score, mean±SD 15.9±6.2 16.1±6.4 0.555
Peak WBC103, cells/mL, median (IQR) 18 (11–31) 17 (9.1–28.5) 0.045†
Inappropriate initial antibiotic treatment 34 (7.1%) 153 (27.9%) <0.001
Discharge to skilled nursing facility 157 (32.6%) 186 (33.9%) 0.657
Mortality 154 (32.0%) 228 (41.5%) 0.001
Resistant to ceftriaxone: methicillin-resistant Staphylococcus aureus: 190 (34.6%); Pseudomonas aeruginosa: 109 (19.9%); Acinetobacter species: 20 (3.6%); Stenotrophomonas maltophilia: 25 (4.6%);
Ceftriaxone-resistant Enterobacteriaceae: 110 (20.0%); others (Achromobacter, Burkholderia, anaerobes, Enterococcus species, Candida species [isolated from respiratory secretions and pleural ﬂuid]): 89
(16.2%).
HAP deﬁnition: duration of hospitalization before bacteremic pneumonia >2 days.
APACHE=Acute Physiology and Chronic Health Evaluaton, CAP= community-acquired pneumonia, HAP=hospital-acquired pneumonia, ICU= intensive care unit, IQR= interquartile range, SD= standard
deviation, WBC=white blood cell count.
∗
Race also includes: Hispanic, Asian, Native American, unknown.
† By the Mann–Whitney U test.
Community-acquired pneumonia: patients were admitted from home, no previous hospitalizations within 90 days, no previous antibiotics, no chronic hemodialysis, duration of hospitalization before bacteremic
pneumonia of 2 days.
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Taken together, these studies highlight the difﬁculty in using
clinical variables to identify speciﬁc pathogen types.
In addition to identifying risk factors for particular drug-
resistant pathogens, we also tried to assess the impact of drug
resistance on mortality in this very well-deﬁned cohort. It is
interesting that even though CfRE infections more likely received
IIAT, due to the higher rates of resistance to piperacillin–-
tazobactam and cefepime, patients infected with P aeruginosa
had signiﬁcantly higher mortality—a ﬁnding that was conﬁrmed
in the multivariable analysis even after correcting for inappro-
priate antibiotics and severity of disease. This ﬁnding is consistent
with earlier studies highlighting the virulence of P aeruginosa as a
pneumonia pathogen[33,40,41] and our earlier study showing that
P aeruginosa bacteremia had the lowest number needed to treat
with appropriate antibiotic therapy (2.5, 95%CI 2.1–3.1) to save
1 additional life.[42]
The association between MDR status and increased mortality
is well-described, but differs across infections and across bacterial
species. In the case of S aureus, large epidemiological studies
found increased case fatality rates for patients with MRSA
bloodstream infections.[43–45] However, in most of these
population-based studies, the authors were unable to control
for the appropriateness of initial antibiotic therapy or acuity of
illness, and their results have not been fully replicated in
comprehensive cohort studies that have found no differences in
mortality between MRSA and MSSA across races, age groups,
and healthcare systems.[46–48] A small study looking speciﬁcally
at MRSA bacteremic pneumonia during an MRSA outbreak
underlined the importance of adequately matching the 2
groups.[49] Similarly, a recent multicenter, multinational study
of pneumonia caused by P aeruginosa found that MDR status
was independently associated with mortality.[50] Two other
Table 4
Variables associated with methicillin-resistant Staphylococcus aureus, Pseduomonas aeruginosa, and ceftriaxone-resistant Enter-
obacteriaceae bacteremic pneumonia in multivariable logistic regression analyses.
MRSA Pseduomonas aeruginosa CfRE
Variable OR (95% CI) P OR (95% CI) P OR (95% CI) P
Age, y
∗
0.99 (0.98–0.99) 0.011
Immunosuppression 0.6 (0.4–0.9) 0.011 2.8 (1.8–4.4) 0.001
Central vein catheter 0.7 (0.5–0.95) 0.025 2.9 (1.8–4.9) 0.001
Admitted from home 0.5 (0.4–0.75) 0.000
APACHE II score
∗
1.1 (1.03–1.1) 0.001
Prior hospitalization 2 (1.2–3.2) 0.003
Prior antibiotics 2.3 (1.4–3.8) 0.001
APACHE=Acute Physiology and Chronic Health Evaluation, CfRE= ceftriaxone-resistant Enterobacteriaceae, CI= conﬁdence interval, MRSA=methicillin-resistant Staphylococcus aureus, OR=odds ratio.
∗
1-point increments in age (years) and in APACHE II score.
Table 3
Comparison of methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, and ceftriaxone-resistant Enterobacteriaceae
bacteremic pneumonia.
Characteristic MRSA (n=190) Pseudomonas aeruginosa (n=109) CfRE (n=110) P value
Age, y, mean±SD 56.9±15.5 59±14.7 59.2±16.5 0.483
∗
Male sex 105 (55.3%) 67 (61.5%) 64 (58.2%) 0.575
Nursing home residence 25 (13.2%) 14 (12.8%) 14 (12.7%) 0.993
Hemodialysis 23 (12.1%) 9 (8.3%) 16 (14.5%) 0.356
Immunosuppression 43 (22.6%) 67 (61.5%) 44 (40.0%) 0.001
Prior hospitalization 85 (44.7%) 71 (65.1%) 50 (45.5%) 0.005
Prior antibiotics 93 (49.0%) 68 (62.4%) 82 (74.5%) 0.001
Charlson score 5±3.4 6±3.4 5.5±3.3 0.901
∗
Central vein catheter 74 (38.9%) 68 (62.4%) 81 (73.6%) 0.001
Surgery 0.096
Abdominal 12 (6.3%) 5 (4.5%) 12 (10.9%)
Nonabdominal 30 (15.8%) 20 (18.3%) 27 (24.5%)
Duration of hospitalization before bacteremia, d, median (IQR) 0 (0–6) 2 (0–12) 8.5 (0–19) 0.001
∗
Mechanical ventilation 88 (46.3%) 49 (45.0%) 56 (50.9%) 0.642
Septic shock 97 (51.1%) 65 (59.6%) 56 (50.9%) 0.302
APACHE II score, mean±SD 15.8±6.2 18±6.9 15.5±6 0.322
∗
Peak WBC103, cells/mL, median (IQR) 19.1 (11.3–30) 15.0 (4.2–28) 16.8 (9.5–28.3) 0.015∗
Resistance to piperacillin–tazobactam 9 (8.3%) 97 (88.2%) 0.001
Resistance to cefepime 8 (7.3%) 16 (14.5%) 0.100
Resistance to meropenem 16 (14.7%) 5 (4.5%) 0.009
Inappropriate initial antibiotic treatment 27 (14.2%) 19 (17.4%) 31 (28.2%) 0.011
Discharge to skilled nursing facility 67 (35.3%) 29 (26.6%) 47 (42.7%) 0.043
Mortality 67 (35.3%) 59 (54.1%) 34 (30.9%) 0.001
APACHE=Acute Physiology and Chronic Health Evaluaton, CfRE=ceftriaxone resistant Enterobacteriaceae, IQR= interquartile range, MRSA=methicillin-resistant Staphylococcus aureus, SD= standard
deviation, WBC=white blood cell.
∗
By the Kruskal–Wallis test for nonparametric data expressed as the median and IQR and by 1-way ANOVA for parametric data expressed as mean±SD.
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studies focusing on Pseudomonas bacteremia also found that
MDR infection remained as an independent predictor for
mortality even after adjusting for IIAT.[51,52] The higher
mortality rates observed with Pseudomonas bacteremic pneu-
monia compared with CfRE bacteremic pneumonia is likely due
to the virulence of the pathogen and the compromised health
status of the infected patients.[53,54] This is also supported by the
recent ﬁndings of Peña et al[55] who found that speciﬁc virulence
factors in P aeruginosa bloodstream infections such as type III
secretion system genotypes were associated with high early
mortality.
Several limitations of our study should be recognized. First, the
retrospective design did not allow for determination of the cause
of mortality. Furthermore, it is possible that we did not identify
all cases of bacteremic pneumonia given the constraints of our
deﬁnition. Second, the data were derived from a single center, and
this necessarily limited the generalizability of our ﬁndings. As
such, our results may not reﬂect what one might see at other
institutions. For example, Barnes-Jewish Hospital has a regional
referral pattern that includes community hospitals, regional long-
term acute care hospitals, nursing homes, and chronic wound,
dialysis, and infusion clinics. Patients transferred from these
settings are more likely to be infected with potentially antibiotic-
resistant bacteria. This may explain the relatively high rates of
infection with potentially antibiotic-resistant Gram-negative
bacteria and S aureus. Third, we did not address antibiotic
pharmacokinetics as a potential contributor to mortality in this
cohort. Another limitation of our study is that some of the
variables identiﬁed as risk factors for infection with speciﬁc
pathogens are not intuitively linked with those pathogens. For
example, the presence of a central vein catheter, known to be
associated with MRSA bloodstream infections, was found to be
linked to infection with CfRE. This may be due to the presence of
a central vein catheter being a marker for infection with CfRE
rather than playing a direct role in the pathogenesis of CfRE
bacteremic pneumonia. Finally, we did not include a control
group of patients without bacteremic pneumonia.
In summary, our study represents the largest study of patients
with bacteremic pneumonia published to date. We found that
IIAT seems to be the most important independent determinant of
mortality and is the only identiﬁed mortality predictor amenable
to intervention.Moving forward, clinicians need to develop novel
approaches for the treatment of patients with bacteremic
pneumonia that achieve timely application of appropriate
antibiotic therapy while avoiding the unnecessary use of
antibiotics, especially broad-spectrum agents. Advances in
new antibiotic development along with rapid diagnostics offer
approaches for achieving this important balance.[56]
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